Abstract
Multiparameter flow cytometry offers the unique ability to simultaneously assess and correlate multiple cellular properties at the single cell level in a timely and efficient manner. Application of this technique to the detection of residual acute leukemia after therapy has been shown to be of singular importance to monitor response to therapy and provide prognostic information. Principles and methods that allow for the sensitive detection of acute leukemia following therapy are presented. The basic protocol outlines a simple and efficient method for the labeling of white cells with monoclonal antibodies directed against cell surface antigens. A second method describes a general method for the simultaneous assessment of surface and cytoplasmic antigens using a combination of fixation followed by membrane permeabilization. An illustrative panel of validated reagents currently in use for residual disease detection for acute lymphoblastic leukemia of B or T cell lineage as well as acute myeloid leukemia is provided. Principles of data analysis that allow for the reproducible detection of small populations of abnormal hematopoietic cells in peripheral blood and bone marrow are presented.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Wood BL (2004) Multicolor immunophenotyping: human immune system hematopoiesis. Methods Cell Biol 75:559–576
Craig FE, Foon KA (2008) Flow cytometry immunophentoyping for hematopoietic neoplasms. Blood 111:3941–3967
Vidriales MB, San-Miguel JF, Orfao A, Coustan-Smith E, Campana D (2003) Minimal residual disease monitoring by flow cytometry. Best Pract Res Clin Haematol 16:599–612
Weir EG, Cowan K, LeBeau P, Borowitz MJ (1999) A limited antibody panel can distinguish B-precursor acute lymphoblastic leukemia from normal B precursors with four color flow cytometry: implications for residual disease detection. Leukemia 13:558–567
Al-Mawali A, Gillis D, Hissaria P, Lewis I (2008) Incidence, sensitivity, and specificity of leukemia-associated phenotypes in acute myeloid leukemia using specific five-color multiparameter flow cytometry. Am J Clin Pathol 129:934–945
Wood B (2006) 9 and 10 color flow cytometry in the clinical laboratory. Arch Pathol Lab Med 130:680–690
Coustan-Smith E, Song G, Clark C, Key L, Liu P, Mehrpooya M et al (2011) New markers for minimal residual disease detection in acute lymphoblastic leukemia. Blood 117:6267–6276
Borowitz MJ, Devidas M, Hunger SP, Bowman WP, Carroll AJ, Carroll WL et al (2008) Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children’s Oncology Group study. Blood 111:5477–5485
Bruggemann M, Raff T, Flohr T, Gökbuget N, Nakao M, Droese J et al German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia (2006) Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia. Blood 107:1116–1123
Krampera M, Vitale A, Vincenzi C, Perbellini O, Guarini A, Annino L et al (2003) Outcome prediction by immunophenotypic minimal residual disease detection in adult T-cell acute lymphoblastic leukaemia. Br J Haematol 120:74–79
Borowitz MJ, Pullen DJ, Shuster JJ, Viswanatha D, Montgomery K, Willman CL et al Children’s Oncology Group study (2003) Minimal residual disease detection in childhood precursor-B-cell acute lymphoblastic leukemia: relation to other risk factors. A Children’s Oncology Group study. Leukemia 17:1566–1572
Bjorklund E, Mazur J, Soderhall S, Porwit-MacDonald A (2003) Flow cytometric follow-up of minimal residual disease in bone marrow gives prognostic information in children with acute lymphoblastic leukemia. Leukemia 17:138–148
Dworzak MN, Froschl G, Printz D, Mann G, Pötschger U, Mühlegger N et al Austrian Berlin-Frankfurt-Münster Study Group (2002) Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia. Blood 99:1952–1958
Coustan-Smith E, Sancho J, Hancock ML, Boyett JM, Behm FG, Raimondi SC et al (2000) Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. Blood 96:2691–2696
Al-Mawali A, Gillis D, Lewis I (2009) The use of receiver operating characteristic analysis for detection of minimal residual disease using five-color multiparameter flow cytometry in acute myeloid leukemia identifies patients with high risk of relapse. Cytometry B Clin Cytom 76:91–101
Kern W, Voskova D, Schoch C, Hiddemann W, Schnittger S, Haferlach T (2004) Determination of relapse risk based on assessment of minimal residual disease during complete remission by multiparameter flow cytometry in unselected patients with acute myeloid leukemia. Blood 104:3078–3085
Buccisano F, Maurillo L, Gattei V, Del Poeta G, Del Principe MI, Cox MC et al (2006) The kinetics of reduction of minimal residual disease impacts on duration of response and survival of patients with acute myeloid leukemia. Leukemia 20:1783–1789
San Miguel JF, Vidriales MB, López-Berges C, Díaz-Mediavilla J, Gutiérrez N, Cañizo C et al (2001) Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification. Blood 98:1746–1751
Wood BL, Levin GR (2006) Interactions between mouse IgG2 antibodies are common and mediated by plasma C1q. Cytometry B Clin Cytom 70:321–328
Gaipa G, Basso G, Aliprandi S, Migliavacca M, Vallinoto C, Maglia O et al I-BFM-ALL-FCM-MRD-Study Group (2008) Prednisone induces immunophenotypic modulation of CD10 and CD34 in nonapoptotic B-cell precursor acute lymphoblastic leukemia cells. Cytometry B Clin Cytom. 74:150–5
Borowitz MJ, Pullen DJ, Winick N, Martin PL, Bowman WP, Camitta B (2005) Comparison of diagnostic and relapse flow cytometry phenotypes in childhood acute lymphoblastic leukemia: implications for residual disease detection: a report from the Children’s Oncology Group. Cytometry B Clin Cytom 68:18–24
Baer MR, Stewart CC, Dodge RK, Leget G, Sulé N, Mrózek K et al (2001) High frequency of immunophenotype changes in acute myeloid leukemia at relapse: implications for residual disease detection (Cancer and Leukemia Group B Study 8361). Blood 97:3574–3580
Langebrake C, Brinkmann I, Teigler-Schlegel A, Creutzig U, Griesinger F, Puhlmann U et al (2005) Immunophenotypic differences between diagnosis and relapse in childhood AML: implications for MRD monitoring. Cytometry B Clin Cytom 63:1–9
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer Science+Business Media, New York
About this protocol
Cite this protocol
Wood, B.L. (2013). Flow Cytometric Monitoring of Residual Disease in Acute Leukemia. In: Czader, M. (eds) Hematological Malignancies. Methods in Molecular Biology, vol 999. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-62703-357-2_8
Download citation
DOI: https://doi.org/10.1007/978-1-62703-357-2_8
Published:
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-62703-356-5
Online ISBN: 978-1-62703-357-2
eBook Packages: Springer Protocols